In this Healio Video Perspective from Hawaiian Eye 2025, Greg Kunst, CEO of Aurion Biotech, discusses positive phase 1/2 data for the company’s cell therapy for corneal endothelial disease.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback